Suppr超能文献

仓鼠肝脏总低密度脂蛋白受体水平的测定。

Measurement of total hepatic low density lipoprotein receptor levels in the hamster.

作者信息

Cosgrove P G, Gaynor B J, Harwood H J

机构信息

Department of Metabolic Diseases, Pfizer Central Research, Pfizer, Inc., Groton, CT 06340.

出版信息

J Lipid Res. 1993 Nov;34(11):1983-2003.

PMID:8263422
Abstract

The ability to measure the total concentration of low density lipoprotein (LDL) receptors in hepatic tissues is of crucial importance to understanding changes in hepatic cholesterol metabolism. Such measurements can be made in conjunction with estimates of LDL receptor transcriptional activity, cell surface LDL receptor number, and rates of hepatic LDL uptake to evaluate the mechanisms controlling cellular LDL receptor expression. Current methods for assessing hepatic LDL receptor levels use microsomes as a source of LDL receptor, and thus rely on consistent contamination of the microsomal preparation with LDL receptor-containing plasma membranes, endocytic vesicles, and/or secretory vesicles. Because this contamination is variable, and may vary with alterations in either the distribution of LDL receptors among the various cellular membrane fractions or in the composition of the intracellular membranes, measurement of LDL receptor concentration in microsomal fractions may not accurately reflect the total compliment of LDL receptors within the cell. We have developed the methodology for isolating the full complement of hepatic LDL receptor containing membranes by discontinuous sucrose density gradient centrifugation, and for quantitating LDL receptor concentration using a Western immunoblotting procedure that uses an anti-C-terminal LDL receptor peptide polyclonal antiserum and assesses the intensity of color formation by reflectance densitometry. Using this methodology, we observed a 126 kDa immunoreactive band for the bovine adrenal cortex LDL receptor that also exhibited LDL binding activity as visualized by biotinylated LDL-ligand blotting, and a doublet of 140 kDa for the hamster liver LDL receptor. These bands were not observed when ligand blotting was conducted in the presence of either 10 mM EDTA or a 5-fold excess of unlabeled LDL, or when immunoblotting was conducted using either preimmune serum or antiserum that had been preabsorbed with LDL receptor peptide. The intensity of color formation was a linear function of the amount of membrane extract separated by electrophoresis. Intra-assay variation averaged 7%, and inter-animal variation averaged 20%. Cholestyramine, tiqueside, CP-88488, 17 alpha-ethinyl estradiol, mevinolin, and the combination of cholestyramine plus mevinolin, pharmacological interventions known to increase LDL receptor activity in experimental animals, produced the predicted increases in hamster total hepatic LDL receptor concentration that were highly correlated with concomitant increases in HMG-CoA reductase activity and reductions in serum cholesterol.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

测量肝组织中低密度脂蛋白(LDL)受体的总浓度对于理解肝脏胆固醇代谢的变化至关重要。这种测量可以与LDL受体转录活性、细胞表面LDL受体数量以及肝脏LDL摄取率的估计相结合,以评估控制细胞LDL受体表达的机制。目前评估肝脏LDL受体水平的方法使用微粒体作为LDL受体的来源,因此依赖于微粒体制备物始终被含LDL受体的质膜、内吞小泡和/或分泌小泡污染。由于这种污染是可变的,并且可能随LDL受体在各种细胞膜组分中的分布变化或细胞内膜的组成变化而变化,因此测量微粒体组分中LDL受体浓度可能无法准确反映细胞内LDL受体的总量。我们已经开发出通过不连续蔗糖密度梯度离心分离含肝脏LDL受体膜的完整组分的方法,以及使用蛋白质免疫印迹法(Western immunoblotting)定量LDL受体浓度的方法,该方法使用抗C末端LDL受体肽多克隆抗血清,并通过反射密度测定法评估显色强度。使用这种方法,我们观察到牛肾上腺皮质LDL受体有一条126 kDa的免疫反应带,通过生物素化LDL配体印迹法也显示出LDL结合活性,仓鼠肝脏LDL受体有一条140 kDa的双峰带。当在10 mM EDTA存在下或5倍过量未标记LDL存在下进行配体印迹时,或者当使用免疫前血清或已用LDL受体肽预吸收的抗血清进行免疫印迹时,未观察到这些条带。显色强度是电泳分离的膜提取物量的线性函数。实验内变异平均为7%,动物间变异平均为20%。消胆胺、替喹西得、CP - 88488、炔雌醇、美伐他汀以及消胆胺加美伐他汀的组合,这些在实验动物中已知可增加LDL受体活性的药物干预措施,使仓鼠肝脏LDL受体总浓度产生了预期的增加,这与HMG - CoA还原酶活性的相应增加和血清胆固醇的降低高度相关。(摘要截短至400字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验